Innovex Expands Platform With Highly Accretive Acquisition of Citadel Casing Solutions
Founded in 2016 by a team of industry experts, Citadel is a leading provider of differentiated downhole technologies which are designed to improve its customers' economics by driving reduced cycle times through improved operational efficiencies.
The acquisition is financially attractive even prior to expected synergies. The transaction values Citadel at approximately 3.8x LTM Adjusted EBITDA1 and is 8% accretive to Innovex's EPS2. Innovex anticipates realizing approximately $2 million of cost synergies within 3 months and anticipates further synergies longer term as the business is fully integrated.
"We are excited to add another strong team and complementary set of products to Innovex's portfolio," said Adam Anderson, CEO of Innovex. "Citadel has successfully grown its business through-cycle by adhering to a culture which is in line with our 'No-Barriers' approach. Citadel's products drive efficiencies by reducing cycle times, and its TrenchFoot™ Wet Shoe technology increases reservoir access resulting in increased production for our customers. As a result of its technology centric approach, Citadel has outgrown the market over the last few years, and we expect this to continue over the next few years. This acquisition bolsters our leadership position in the cementing tool market in US Land and supports our efforts to grow market share in the offshore and international markets."
"We are excited to accelerate our growth under the Innovex banner by tapping into its broad, complementary product portfolio and geographical exposure," said Todd Stair, CEO of Citadel. "The combination of our teams and technologies will enhance our ability to help operators deliver efficient wells, furthering our like-minded mission to help bring reliable and affordable energy to the world."
"The acquisition of Citadel fits perfectly within our M&A framework," said Kendal Reed, CFO of Innovex. "Citadel's portfolio of Big Impact, Small Ticket products has allowed it to achieve rapid, profitable growth while delivering exceptional returns on capital. We were able to acquire Citadel at a favorable multiple and strong acquisition-level returns even before considering revenue and cost synergies. Importantly, the transaction is highly accretive to our earnings and cash flow per share. Given our strong balance sheet and cash flow generative business model, we were able to acquire Citadel in an all-cash transaction while maintaining an extremely conservative leverage profile and an active corporate buyback program. We expect this acquisition to drive ROCE3 well in excess of idle balance sheet cash, improving long-term returns for our shareholders."
Advisors
Akin Gump Strauss Hauer & Feld LLP served as legal advisor to Innovex.
Piper Sandler served as exclusive financial advisor to Citadel, and Troutman Pepper Locke LLP served as Citadel's legal advisor.
About Innovex
Innovex International, Inc (NYSE: INVX) is a Houston-based company established in 2024 following the merger of Dril-Quip, Inc and Innovex Downhole Solutions.
Our comprehensive portfolio extends throughout the lifecycle of the well; and innovative product integration ensures seamless transitions from one well phase to the next, driving efficiency, lowering cost, and reducing the rig site service footprint for the customer.
With locations throughout North America, Latin America, Europe, the Middle East and Asia, no matter where you need us, our team is readily available with technical expertise, conventional and innovative technologies, and ever-present customer service.
About Citadel
Founded in 2016, Citadel was established to revolutionize casing technology through continuous innovation. Citadel's high-quality, reliable downhole tools are used globally, driving efficiency and performance in the Oil and Gas sector. By combining internal R&D with strategic partnerships, Citadel remains at the forefront of technological advancements in casing solutions.
Non-GAAP Financial Measures
Adjusted EBITDA is a non-GAAP financial measure. Innovex defines Citadel's Adjusted EBITDA as net income before interest expense, income tax expense, depreciation and amortization, deal costs and board retention agreements, net, further adjusted to exclude certain items which Citadel believes are not reflective of its ongoing performance or which are non-cash in nature. Citadel management used Adjusted EBITDA to assess the profitability of its business operations and to compare Citadel's operating performance to its competitors without regard to the impact of financing methods and capital structure and excluding costs that management believes do not reflect its ongoing operating performance. Adjusted EBITDA does not represent and should not be considered as an alternative to, or more meaningful than, net income or any other measure of financial performance presented in accordance with GAAP as measures of Citadel's financial performance. Innovex's computation of Citadel's Adjusted EBITDA may differ from computations of similarly titled measures of other companies.
Innovex utilizes Return on Capital Employed ("ROCE") (a non-GAAP measure) to assess the effectiveness of its capital allocation over time and to compare its capital efficiency to its competitors. Innovex defines ROCE as Income from Operations, before acquisition and integration costs and after tax (resulting in Adjusted Income from Operations, after tax) divided by average capital employed. Capital employed is defined as the combined values of debt and stockholders' equity.
Forward-Looking Statements
Certain statements contained in this press release and oral statements made regarding the matters addressed in this release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of Innovex's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.
Forward-looking statements can be identified by the use of forward-looking terminology including "may," "believe," "expect," "intend," "anticipate," "plan," "should," "estimate," "continue," "potential," "will," "hope" or other similar words and include the Company's expectation of future performance contained herein. These statements discuss future expectations or state other "forward-looking" information, including without limitation statements regarding the expected benefits of the acquisition. You are cautioned not to place undue reliance on any forward-looking statements, which can be affected by assumptions used or by risks or uncertainties. Consequently, no forward- looking statements can be guaranteed. These statements reflect management's expectations based on currently available information and involve significant risks, uncertainties and assumptions that may cause actual results to differ materially. Factors that may cause such differences include, but are not limited to, economic conditions and other factors noted in the Company's Annual Report on Form 10-K, any Quarterly Reports on Form 10-Q and the other documents that the Company files with the Securities and Exchange Commission. Innovex disclaims any duty to update and does not intend to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release, except as may be required by law.
________________________________________
1
Citadel's LTM Adjusted EBITDA as of 04/30/2025. Adjusted EBITDA is a non-GAAP measure. A reconciliation of Citadel's LTM Adjusted EBITDA to Citadel LTM net income, the most directly comparable financial measures presented in accordance with GAAP, is outlined in the reconciliation table accompanying this release.
2
Reflects LTM as-reported net income for both Innovex and Citadel as of 03/31/2025. The net income amount does not give effect to costs, charges, synergies, or other similar items that could result from a combined company. The share count uses Innovex's outstanding share count as of 03/31/2025. As Citadel is a passthrough entity, Citadel did not incur any income tax expenses. As a combined company, income tax expenses would be expected. Therefore, for the purpose of calculating EPS, an assumed tax rate of 21% was used.
3
Return on Capital Employed ("ROCE") is a non-GAAP measure.
Innovex International, Inc.
Reconciliation of Citadel's Net Income to Adjusted EBITDA
(in thousands)
(Unaudited)
CitadelLTM
April 30, 2025
Revenue
$
71,965
Net Income
$
15,098
Interest expense
513
Income tax expense
-
Depreciation and amortization
2,600
Other expense/income
-
EBITDA
$
18,212
Deal Costs
185
Board Retention Agreements
64
Adjusted EBITDA
$
18,461
Net Income (Loss) % Revenue
21
%
Adjusted EBITDA Margin1
26
%
Note: Figures shown above reflect unaudited results. A quality of earnings analysis was conducted to verify the figures shown.
(1) Underlying calculation is not rounded.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250602971078/en/
Contacts
Investor Relations Contact Avinash CuddapahSr. Director – Investor Relationsinvestors@innovex-inc.com (346) 398-0000
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Up Over 100% Year to Date, Is Roblox Stock a No-Brainer Buy?
Key Points Roblox bounced back from its post-pandemic slowdown. It's keeping its tween users as it gains a higher mix of older and overseas users. It still looks reasonably valued, but it hasn't proven its business is sustainable yet. 10 stocks we like better than Roblox › Roblox's (NYSE: RBLX) stock has more than doubled since the beginning of 2025. The gaming platform company attracted a lot of attention again as it gained more daily active users (DAUs), locked them in for more hours, and accelerated its bookings growth. But even after that impressive rally, Roblox's stock remains about 12% below its all-time high from November 2021. Should investors buy it now and expect it to set new record highs? Roblox's niche is still expanding Roblox's gaming platform allows its users to create their own games with a simple block-based system that doesn't require any prior coding knowledge. They can share those games with other players and monetize them with an in-game currency called Robux. Roblox's players can buy Robux on an a la carte basis or through discounted subscriptions, while creators can accumulate it and cash it in for real-world currencies. That creator-driven flywheel makes it more similar to Alphabet's YouTube than other gaming development platforms like Unity. Roblox became a household name during the pandemic, when stay-at-home restrictions drove many tween creators and players to its platform. It experienced a slowdown in 2022 after it lapped that growth spurt, but it continued to expand by gaining older and overseas users. In 2023 and 2024, Roblox's total bookings (which mainly come from its Robux sales), DAUs, average bookings per DAU (ABPDAU), and total hours engaged all grew at a healthy rate. Metric 2021 2022 2023 2024 Bookings growth 45% 5% 23% 24% DAU growth 40% 23% 22% 21% ABPDAU growth 4% (14%) 0% 2% Hours engaged growth 35% 19% 22% 23% Data source: Roblox. Roblox's ABPDAU growth stabilized as it more effectively monetized its older and overseas users -- which initially generated lower bookings than its core tween users in the U.S. and Canada. It also expanded its advertising ecosystem as more brands launched metaverse experiences on its platform, which were more engaging than traditional ads. That acceleration continued in the first quarter of 2025, as bookings increased 31% year over year, DAUs grew 26% to 97.8 million, ABPDAU improved 4%, and hours engaged climbed 30% to 21.7 million. For the full year, analysts expect bookings to grow 27% as adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rises 47%. That robust growth counters the notion that Roblox was a pandemic-era fad. Near-term catalysts and challenges Roblox's near-term growth could be driven by its new breakout titles, including Grow a Garden and 99 Nights in the Forest; the expansion of its metaverse advertising platform; the rollout of its more advanced developer tools; and its overseas expansion. From 2024 to 2027, analysts expect Roblox's bookings and adjusted EBITDA to increase at a CAGR of 22% and 37%, respectively. With an enterprise value of $79 billion, the stock still seems reasonably valued at 12 times next year's bookings and 49 times its adjusted EBITDA. However, Roblox is expected to stay unprofitable for the foreseeable future. It's ramping up its infrastructure spending to support its expanding platform, increasing its investments in stronger safeguards for its younger users, and will continue to subsidize salaries with high stock-based compensation expenses (which consumed 23% of its bookings in 2024). It will also continue to pay high developer exchange fees (the cash it pays its creators for trading in their Robux) to lock in its higher-value creators. So is Roblox a no-brainer buy right now? Roblox is still expanding at an impressive rate, but it hasn't proven its business model is sustainable yet. Its high debt-to-equity ratio of 24.1 (which includes over $1 billion in long-term debt) could also make it hard to raise fresh cash at reasonable rates. That might be why Robolox insiders also sold nearly nine times the number of shares they bought over the past 12 months. So while Roblox might keep growing over the next decade, I wouldn't call it a "no-brainer" buy right now. It could have a bright future, but investors should gradually accumulate shares instead of blindly chasing the recent rally -- which could easily fizzle out in a market downturn. Should you invest $1,000 in Roblox right now? Before you buy stock in Roblox, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Roblox wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $630,291!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,791!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Roblox, and Unity Software. The Motley Fool has a disclosure policy. Up Over 100% Year to Date, Is Roblox Stock a No-Brainer Buy? was originally published by The Motley Fool


Business Wire
24 minutes ago
- Business Wire
Davis Bynum Wines Celebrates 50 Years with Exclusive Anniversary Wine Collection
HEALDSBURG, Calif.--(BUSINESS WIRE)-- Davis Bynum Wines, a pioneering force in Russian River Valley Pinot Noir, proudly announces the release of its 50th Anniversary Wine Collection. This limited-edition series pays tribute to Davis Bynum's groundbreaking legacy and the iconic vineyards that helped shape the Russian River Valley wine region. Davis Bynum Wines, a pioneering force in Russian River Valley Pinot Noir, proudly announces the release of its 50th Anniversary Wine Collection. Share The 50th Anniversary Collection marks Davis Bynum's most exclusive release to date - featuring small-lot wines sourced from legendary vineyards with deep historical ties to founder Davis Bynum. Each wine in the collection tells a unique story, honoring the innovative spirit of Davis and the multi-generational farming families of Sonoma County. "This collection is a true love letter to the Russian River Valley and to Davis Bynum's enduring vision," says Greg Morthole, Winemaker for Davis Bynum Winery. "We crafted these wines to showcase the incredible sense of place and history found in these vineyards. They are elegant, expressive, intentionally made wines, representing the pinnacle of the Russian River Valley's legacy." The collection includes: Dutton Origin Chardonnay: Sourced from the original 1967 Wente clone planting at the Dutton Home Ranch, this Chardonnay is a rare gem. Only six barrels were produced from these low-yielding, historic vines, making it the first time Davis Bynum has had access to this exceptional fruit. It offers an amazing balance of acidity and richness with notes of Opal apple, poached pear, and crème brûlée. Bacigalupi Pinot Noir: This Pinot Noir comes from the legendary Bacigalupi Vineyard, renowned for being the vineyard source for the wine that won the famed 1976 Paris tasting. The single-clone Dijon 667 from its Frost Ranch site in the Middle Reach delivers a riper, spicier profile with notes of red plum, raspberry jam, toffee, and spice, balanced by vibrant acidity and signature region-defining complexity. Rochioli Pinot Noir: The crown jewel of the collection, this anniversary Pinot is made from the celebrated Rochioli Vineyard – the same site Davis Bynum produced the very first single-vineyard Pinot Noir from, released 50 years ago. With a tiny production of only 32 cases, this is a highly sought-after wine. The fruit, from a northeast-facing block, ripens slowly and evenly, yielding layers of complexity and elegance. It showcases classic Russian River Valley Pinot Noir notes of ripe strawberry, rhubarb pie, forest floor, and mushroom. Single-bottle wooden boxes are available as a collector's edition. "These wines are for those who appreciate coveted vineyards, and the delicious grapes they produce," adds Anthony 'AC' Capobianco, SVP of Global Sales & Marketing for Rodney Strong Wine Estates. "We expect this exclusive collection to sell out quickly, as these wines are not available in stores or restaurants – only direct from our winery. This is a rare opportunity for collectors and enthusiasts to acquire truly special bottles that celebrate our rich heritage." The Davis Bynum 50th Anniversary Wine Collection is available online. Due to the extremely limited production, consumers and buyers are encouraged to inquire promptly. About Rodney Strong Wine Estates Rodney Strong Wine Estates is a family-owned wine company that includes Rodney Strong Vineyards, Davis Bynum Wines, and ROWEN Wine Company. Rodney Strong Wine Estates sustainably farms twelve estate vineyards and produces wines from Sonoma County's finest appellations – Alexander Valley, Russian River Valley, Chalk Hill, Knights Valley, and the Sonoma Coast. Rodney Strong Vineyards was founded in 1959 by Sonoma County wine pioneer Rodney D. Strong as the 13th bonded winery in the county. The company aspires to conserve and protect the environment in all its operations through sustainable practices, solar power, and fish-friendly farming. The Klein family, a fourth generation California farming family, entered the wine business with the purchase of Rodney Strong Vineyards in 1989. Learn more at
Yahoo
an hour ago
- Yahoo
Why Eli Lilly Stock Was Looking Sickly Today
Key Points Investors were spooked by a peer's notable reduction in sales and profitability guidance. This peer was Novo Nordisk, which like Eli Lilly sells a popular drug approved specifically for obesity. 10 stocks we like better than Eli Lilly › One of the more popular stocks in the pharmaceutical sector of late got the cold shoulder from investors on Tuesday. Eli Lilly (NYSE: LLY) closed today's trading session down by almost 6% in value, which was notably worse than the 0.3% drop of the bellwether S&P 500 index. That decline wasn't necessarily Eli Lilly's fault, though. Reducing weight, reducing guidance Eli Lilly's recent popularity is due in no small measure to its plunge into the highly lucrative weight-loss drug market. In late 2023, its Zepbound -- essentially the same treatment as its diabetes drug Mounjaro -- was approved to treat obesity, and the company was off to the races. On Tuesday, though, the standard-bearer for the segment took quite a tumble. That was Novo Nordisk, which this morning lowered its guidance for both full-year sales and operating profit. The growth forecast for the former was reduced to 8% to 14% over the 2024 tally (previous guidance range: 13% to 21%). Ditto for operating profit, which is now expected to rise in a range of 10% to 16%. That would be encouraging, if it weren't for the fact that management's preceding prediction was 16% to 24%. Novo Nordisk is known for developing and selling Wegovy, the first GLP-1 drug approved by the U.S. Food and Drug Administration specifically for weight loss. The company has flown to renown and admiration on the wings of that drug, which remains a key product. Investors probably fear that Eli Lilly's Zepbound will also perform worse than expected. Not an emergency I don't think anyone should push the panic button on Eli Lilly due to this (or Novo Nordisk, while I'm at it). Demand for obesity drugs remains strong and nearly unlimited, so both Zepbound and Wegovy -- which still benefit from a lack of competitors, at least for now -- should continue to be growth drivers. Also, in the case of Eli Lilly, the sprawling pharmaceutical company has a vast portfolio and a very wide development pipeline, so it's hardly dependent on one drug -- no matter how currently popular that drug might be. Should you buy stock in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $633,452!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,083,392!* Now, it's worth noting Stock Advisor's total average return is 1,046% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Eli Lilly Stock Was Looking Sickly Today was originally published by The Motley Fool